Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial

Poolman, 2015, Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field, J Infect Dis, 213, 6, 10.1093/infdis/jiv429 Russo, 2003, Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem, Microbes Infect, 5, 449, 10.1016/S1286-4579(03)00049-2 Jackson, 2005, Burden of community-onset Escherichia coli bacteremia in seniors, J Infect Dis, 191, 1523, 10.1086/429344 Bou-Antoun, 2016, Descriptive epidemiology of Escherichia coli bacteraemia in England, April 2012 to March 2014, Euro Surveill, 21, 30329, 10.2807/1560-7917.ES.2016.21.35.30329 Foxman, 2014, Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden, Infect Dis Clin North Am, 28, 1, 10.1016/j.idc.2013.09.003 Mathers, 2015, Escherichia coli ST131: the quintessential example of an international multiresistant high-risk clone, Adv Appl Microbiol, 90, 109, 10.1016/bs.aambs.2014.09.002 Cross, 1990, Escherichia coli and Klebsiella vaccines and immunotherapy, Infect Dis Clin North Am, 4, 271, 10.1016/S0891-5520(20)30341-X Huttner, 2017, Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial, Lancet Infect Dis, 17, 528, 10.1016/S1473-3099(17)30108-1 Ihssen, 2010, Production of glycoprotein vaccines in Escherichia coli, Microb Cell Fact, 9, 61, 10.1186/1475-2859-9-61 2007 Abbanat, 2017, Development and qualification of an opsonophagocytic killing assay to assess immunogenicity of a bioconjugated Escherichia coli vaccine, Clin Vaccine Immunol, 24, e00123, 10.1128/CVI.00123-17 1997, Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep, 46, 1 Henckaerts, 2007, Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children, Vaccine, 25, 2518, 10.1016/j.vaccine.2006.09.029 Schuerman, 2011, Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption, Clin Vaccine Immunol, 18, 2161, 10.1128/CVI.05313-11 van Deursen, 2017, Immunogenicity of the 13-valent pneumococcal conjugate vaccine in older adults with and without comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), Clin Infect Dis, 65, 787, 10.1093/cid/cix419 Bonten, 2015, Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults, N Engl J Med, 372, 1114, 10.1056/NEJMoa1408544